GlassScriptPhysician profile
Neelam Todi
NPI 1427084268
$7,008.69
in general payments reported to CMS, 2019-2025
25 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $385 · 2021: $180 · 2022: $4,289 · 2023: $825 · 2024: $241 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.07 |
| Education | $215.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $3,784.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $870.27 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $371.31 | 2019-2025 | Lynparza, Enhertu |
| Incyte Corporation | $325.96 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $147.94 | 2020-2022 | |
| Janssen Biotech, INC. | $143.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Stemline Therapeutics INC. | $125.00 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $116.02 | 2019 | |
| Amgen INC. | $114.91 | 2019-2020 | |
| Astellas Pharma US INC | $114.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $100.00 | 2019 | |
| Medtronic, INC. | $96.15 | 2023 | Solitaire X |
| Celgene Corporation | $93.50 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $74.78 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $74.09 | 2021 | |
| Sirtex Medical INC | $40.88 | 2022-2023 | Sir-Spheres Microspheres |
| Adaptive Biotechnologies Corporation | $32.78 | 2022-2025 | Clonoseq |
| Pfizer INC. | $29.65 | 2022-2024 | |
| Beigene USA, INC. | $25.72 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $24.49 | 2022 | |
| Sobi, INC | $18.68 | 2022 | |
| Daiichi Sankyo INC. | $14.31 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelam Todi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.